DeepHealth, a wholly-owned subsidiary of RadNet (RDNT), has received expanded FDA 510(k) clearance for its mammography software. SmartMammo Dx, the AI algorithm within SmartMammo, is now FDA-cleared to be compatible with GE HealthCare’s (GEHC) Senographe Pristina mammography systems. SmartMammo Dx was first cleared in May 2021 in conjunction with Hologic mammography systems, where its performance has also been tested and cleared in patients with unilateral breasts and with breast implants. “This newly expanded clearance advances DeepHealth’s mission to enhance and expand breast cancer screening programs by broadening system compatibility,” the company stated.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDNT:
- RadNet price target raised to $94 from $80 at Truist
- RadNet’s DeepHealth expands FDA clearance for SmartMammo solutionGE
- RadNet Achieves Record Revenue and Adjusts 2024 Guidance
- Cigna drops pursuit of Humana: Morning Buzz
- GE HealthCare and RadNet collaborate in imaging systems innovation
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
